United States: FTC Hosts Workshop – "Understanding Competition In Prescription Drug Markets: Entry And Supply Chain Dynamics"

Last Updated: November 14 2017
Article by Shawn N. Skolky

On Wednesday, November 8, 2017 the Federal Trade Commission (FTC) hosted a workshop seeking to explore the general question of why the cost of prescription drugs has risen greatly in recent history. The Workshop was framed around industry development in the time since the enactment of the Hatch-Waxman Act in 1984.

Acting Chairman Maureen Ohlhausen gave the first keynote address. Chairman Ohlhausen was quick to note that after a branded drug’s patent expires, the first generic drug entry into the market offers a 20-30% discount, with subsequent entries lowering the price up to 85% or more. She questioned how to best encourage greater entry into the generic marketplace, particularly when the demand for a drug is not sufficiently high. Ms. Ohlhausen touted the Agency’s recent history with enforcement actions, but cautioned those in attendance not to draw conclusions about the FTC’s forthcoming plans. Instead, Ms. Ohlhausen framed the workshop as an opportunity to explore potential solutions to difficult problems. In closing, she asserted that the antitrust process works best when it focuses on eradicating harms to the competitive process, and if the FTC does take enforcement actions in this space, it will be based upon the specific facts of a case, rather than as a blanket admonition of certain practices.

Dr. Scott Gottlieb, FDA Commissioner made the second keynote speech, and discussed the FTC and FDA’s shared goal of ensuring that consumers benefit from greater competition in the prescription drug market. Dr. Gottlieb noted that while there have been many advancements in pharmaceutical products, consumers may only see benefits if they are able to afford them. Dr. Gottlieb believes that the “root cause” of high drug prices is lack of competition, and advocated for brisk competition when exclusivity periods on patented drugs expire. With respect to generic drugs, Dr. Gottlieb espoused his concern that branded companies often make it difficult for generic firms to buy the doses they require in order to appropriately test their products to bring to market.

The panels that followed discussed a variety of issues, beginning with a general discussion of drug supply and demand, and then discussing the issue of intermediaries, including Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs). The panels included great minds from many types of firm, including researchers, economists, trade associations, law firms, and policy advocates.

Panel 1: Generic Drug Competition: Understanding Demand, Price and Supply Issues

One of the hot topics of the Workshop was the issue of increasing competition in the generic drug market. Throughout the presentations, there was one consensus among panelists: entry into the market is affected by profitability. Factors affecting generic drug use that were discussed included: (1) advertising/promotion of brand name drugs; (2) patient/physician skepticism as to effectiveness; (3) cost/availability of generic drugs; and (4) consolidation in the marketplace. Due to these factors, niche patient populations are rarely sought after for development of generic alternatives, where demand is simply not great enough to warrant the significant investment required of bringing a generic drug to market. Multiple panelists throughout the day emphasized that generics operate in a deflationary market, leading generic drug manufacturers to market hundreds of products with varying levels of profitability. This is in stark contrast to the model for “branded” drugs, where companies market a small number of highly profitable products. During the panel discussion, one interesting alternative was raised with respect to drug shortages not resolved by new market entrants. A panelist suggested temporary importation for these periods while generic firms navigate through the typical FDA approval process. Such a strategy would attempt to avoid the rent-seeking behaviors the industry has seen, for example, when Turing Pharmaceuticals raised the price of its antiparasitic drug Daraprim from approximately $13.50 per dose to $750.

Panel 2: Understanding Intermediaries: Pharmacy Benefit Managers

The next panel was the first of two related to intermediaries in the prescription drug marketplace–PBMs. One repeated theme was the concentration of the PBM market. Notably, the three largest PBMs, Caremark, OptumRx, and Express Scripts have approximately 75% market share in the space. This market makeup was compared to the pharmaceutical drug manufacturers, where even the largest of manufacturers control only 6-7% market share. The value of these PBMs was hotly debated. For example, a general proposition was espoused that for every $100 spent on prescription drugs, PBMs keep approximately $5. Therefore, consumers must ask whether PBMs bring at least $5 of value to the market. Anecdotally, one panelist described a scenario in which a PBM would prefer the sale of a drug sold with a higher list and retail price due to greater rebates, and thus profit to the PBM (typically, a PBM retains 10% of the rebate on a drug).

Panelists also advocated for the continued use of PBMs. These organizations provide for improved access and choice for consumers. Instead of PBMs being responsible for the rising cost of prescription drugs, one panelist placed the greatest blame on pharmaceutical industry’s shift from producing drugs that may cost ~$3 per day to “blockbuster” drugs that may cost upwards of $1,000 per day. In fact, one panelist also provided statistics to show that in the face of the growth of PBMs, there has been a modest cost growth per capita as pertains to prescription drugs. These statistics were criticized by others on the panel as including generic drug pricing, which cost substantially less than “branded” drugs.

Panel 3: Understanding Intermediaries: Group Purchasing Organizations

The third panel centered around Group Purchasing Organizations, organizations that allow healthcare providers, including hospitals, nursing homes, etc., to realize cost savings by aggregating purchase volume and negotiate discounts with manufacturers and distributors. Overall, the panelists were in agreement that GPOs are, in general, a good thing. The pros and cons of the organizations were best summed up by the panel moderator, the FTC’s Markus Meir, Acting Deputy Director of the Bureau of Compliance. He asserted that GPOs reduce transaction costs, increase their members’ bargaining power, and secure volume discounts that might otherwise be unavailable to the hospital members. But, critics say that GPOs are fraught with conflicts of interests (principal-agency problems) and that GPOs have played a role in creating drug shortages.

One panelist in particular began his talk with a stipulation: “GPOs do great things. The relevant question is whether they would do even greater things if they didn’t face a conflict of interest when it comes to their compensation?” In essence, he pondered aloud what incentives GPOs have to further lower drug prices if they are paid based on a percentage of the price of the drug – one would believe they would seek to maximize revenue, and therefore benefit from higher prices.

Panel 4: Potential Next Steps to Encourage Entry and Expand Access through Lower Prices

The final panel was a summary panel of two individuals. It was repeated that the high and continually growing price of prescription drugs are a problem for many stakeholders, but most importantly for patients. It was asserted throughout the day, and during this session that “Big Pharma” often pursues monopoly pricing, and there is little that can be done (or has been done) to combat these practices. There are no “silver bullets,” and even well-intentioned solutions can result in bad consequences. The panelists suggested a more aggressive antitrust investigative power and enforcement be utilized by the FTC.


In her closing remarks, FTC Deputy Director from the Office of Policy Planning, Suzanne Munck, was grateful for the robust participation throughout the day. Ms. Munck believed that it was particularly helpful to see the panelists back their arguments up with data, which is most helpful from a policymaker’s perspective.

While the FTC Workshop did not answer all of the industry’s questions, it was undoubtedly a step in the right direction for opening up a dialogue, and may shed light on the FTC’s future agenda, although Acting Chairman Ohlhausen cautioned against any such inferences. Slides from the day’s presentations can be found here and speaker bios can be found here. Public comments may be submitted until December 8, 2017.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Shawn N. Skolky
Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions